We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

6 hedge funds and large institutions have $12.9M invested in Akari Therapeutics in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
6
Holders Change
+6
Holders Change %
–
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$4.75M
2
SM
Sabby Management
Florida
+$4.75M
3
BC
Broadfin Capital
New York
+$3.34M
4
CAM
Cormorant Asset Management
Massachusetts
+$735K
5
DCM
DAFNA Capital Management
California
+$283K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$4.37M +$4.75M +84 New
SM
2
Sabby Management
Florida
$4.34M +$4.75M +84 New
BC
3
Broadfin Capital
New York
$3.06M +$3.34M +59 New
CAM
4
Cormorant Asset Management
Massachusetts
$668K +$735K +13 New
DCM
5
DAFNA Capital Management
California
$285K +$283K +5 New
KCM
6
Knoll Capital Management
Florida
$151K +$170K +3 New
Citigroup
7
Citigroup
New York
$16K – – –
TRCT
8
Tower Research Capital (TRC)
New York
$3K – – –
U
9
UBS
Switzerland
$3K – – –

AKTX Hedge Fund Activity: Q1 2014 in Review

6 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2014, worth a combined $12.9M.

Buyers outnumbered sellers: 6 funds opened new AKTX positions and 0 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $4.75M.

  • 6 institutional investors held Akari Therapeutics (AKTX) as of Q1 2014, up from 0 in Q4 2013.
  • Funds reported $12.9M of Akari Therapeutics stock for Q1 2014.
  • 6 funds opened new Akari Therapeutics positions in Q1 2014 and 0 closed out, a net change of +6 holders.
  • The largest Akari Therapeutics buyer in Q1 2014 was Baker Bros. Advisors, an estimated $4.75M added.

Based on aggregated 13F filings for Q1 2014.